AVENIO ctDNA Analysis Kits

Overview

The AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research. These assays provide an end-to-end tumor profiling and longitudinal tumor burden monitoring solution.

Liquid Biopsy for Next Generation Sequencing

Features and Benefits of AVENIO ctDNA Analysis Kits

  • Flexibility to match the right assay optimized for the right research goal
  • Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

...

Roche Sequencing - ctDNA Targeted Kits for NGS Liquid Biopsy

Explore this NGS liquid biopsy assay with a 17 gene panel containing genes in NCCN guidelines and optimized for lung cancer and colorectal cancer applications.

Learn more
...

Roche Sequencing | ctDNA Expanded Kits for NGS Liquid Biopsy

Explore this NGS liquid biopsy assay with a 197 gene panel and optimized for longitudinal tumor burden monitoring in lung cancer and colorectal cancer.

Learn more
...

Roche Sequencing: ctDNA Surveillance Kits for NGS Liquid Biopsy

Explore this NGS liquid biopsy assay with a 77 gene panel containing genes in NCCN guidelines and emerging biomarkers.

Learn more
  1. National Comprehensive Cancer Network.  October 15, 2016.
  2. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.
  3. Data on file.